Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0001213900-26-004186·Brio Capital Master Fund Ltd.
Schedule 13G ownership disclosure
Sigyn Therapeutics Inc
COMMON STOCK, PAR VALUE $0.0001 · CUSIP: 82674U205
Event date: 2025-12-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Brio Capital Master Fund Ltd.
Shares: 160,537.00 · Class: 9.99%
- Brio Capital Management LLC
Shares: 160,537.00 · Class: 9.99%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001213900-26-004186
- Form type
- SCHEDULE 13G/A
- Filer
- Brio Capital Master Fund Ltd.
- CIK
- CIK 1560894
- Filed
- Jan 14, 2026
- Reporting period
- Dec 31, 2025
- Description
- Schedule 13G beneficial ownership